Pharmaceutical Technology

JUNE 24, 2022

As regulatory agencies gear up for another round of Covid-19 vaccine deliberations centered on emerging variants, Moderna has released data on its booster’s efficacy against Omicron subvariants. 1 variant, on 22 June, Moderna said its booster also showed a “potent” antibody response against Omicron subvariants BA.4

Vaccination 264

Vaccination Vaccine Antibody Medicine 264

Pharmaceutical Technology

MAY 24, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Recombinant viral vector-based medicinal preparations. However, not all innovations are equal and nor do they follow a constant upward trend.

Medicine 130

Medicine Vaccination Vaccine Gene 130

Medical Xpress

FEBRUARY 27, 2023

Then he carefully administers a shot to the animal, much like a pediatrician giving a kid a vaccine. Every four months, pathologist Aaron LeBeau scoops into a net one of the five nurse sharks he keeps in his University of Wisconsin lab.

Antibody 98

Antibody Medicine Nurses Vaccination 98

Scienmag

OCTOBER 21, 2021

WHAT: A booster dose of the mRNA-1273 COVID-19 vaccine given to rhesus macaques about six months after their primary vaccine series significantly increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern, according to a new study from National Institutes of Health scientists and colleagues.

Antibody 70

Antibody Vaccination Vaccine Scientist 70

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Medical Xpress

APRIL 7, 2023

A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including Omicron, the most recent.

Antibody 75

Antibody Research Vaccination Vaccine 75

Pharmaceutical Technology

AUGUST 24, 2022

5 Omicron-targeting bivalent booster vaccine for Covid-19. The submission is made for a 50µg booster dose of the vaccine for usage in adults aged 18 years and above. As against a 50µg booster dose of mRNA-1273 in priorly uninfected subjects, mRNA-1273.214 demonstrated superior neutralising antibody response against Omicron BA.1

Vaccination 130

Vaccination Vaccine Gene Therapy Antibody 130

pharmaphorum

MAY 18, 2022

Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. ” The post AstraZeneca buys into startup RQ Bio’s COVID antibodies appeared first on.

Antibody 98

Antibody Licensing Licensing Medicine 98

Pharmaceutical Technology

APRIL 10, 2023

It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061).

Immune Response 264

Immune Response Antibody Vaccination Vaccine 264

Pharmaceutical Technology

SEPTEMBER 19, 2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AstraZeneca ’s Evusheld (formerly AZD7442) for Covid-19 in the European Union (EU). Additionally, in the trial, the antibody cocktail was found to be well-tolerated.

In-Vitro 279

In-Vitro Antibody Vaccination Vaccine 279

Scienmag

JUNE 10, 2022

Researchers have known for some time that maternal breast milk provides critical nutrients for newborns, and antibodies from mothers vaccinated against a specific disease-causing bacterium or virus can be transferred via breast milk to babies.

Antibody 72

Antibody Bacteria Bacterium Vaccination 72

Medical Xpress

FEBRUARY 22, 2023

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 75

Protein Medicine Production Antibody 75

JAMA Internal Medicine

DECEMBER 19, 2021

This randomized clinical trial evaluated the effectiveness of a third dose of mRNA-based vs a vector-based vaccine in 201 kidney transplant recipients with no SARS-CoV-2 antibodies after 2 prior doses of an mRNA vaccine.

Antibody 74

Antibody Vaccination Vaccine Clinical Trials 74

Drug Discovery World

JANUARY 3, 2023

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . Hugo Fry, CEO of RQ Bio, comments: “We’re delighted that one of our discovered antibodies is now at the core of an innovative AstraZeneca investigational medicine reaching clinical trials.” .

Antibody 52

Antibody Development Immune Response Clinical Trials 52

Scienmag

JANUARY 21, 2022

A recent study looked at the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV2. The findings are published this week […].

Antibody 81

Antibody Vaccination Vaccine Medicine 81

BioTech 365

APRIL 7, 2021

Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New … Continue reading →

Antibody 52

Antibody Medicine Vaccination Vaccine 52

Pharmaceutical Technology

AUGUST 23, 2022

5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5-adapted bivalent vaccine.

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

JAMA Internal Medicine

JANUARY 23, 2022

This comparative effectiveness research study compares antibody levels after ChAdOx1 nCoV-19 vaccination in individuals with or without previous SARS-CoV-1 infection.

Antibody 75

Antibody Vaccination Vaccine Research 75

Advarra

JANUARY 11, 2024

While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines. Personalized medicine using genetic resequencing techniques, such as cell and gene therapies, enables researchers to create more customized therapies for combatting cancer.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

Drug Discovery World

NOVEMBER 2, 2022

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa. . The antibody was up to 88.2% The antibody was up to 88.2% We hope monoclonal antibodies will transform malaria prevention in endemic regions.” .

Antibody 52

Antibody Allergies Trials Medicine 52

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

Scienmag

JULY 1, 2022

Tokyo, Japan – Despite significant and stunning advances in vaccine technology, the COVID-19 global pandemic is not over. Now, investigators from Japan have developed a new antibody-based method for the rapid and reliable detection of SARS-CoV-2 […].

Antibody 95

Antibody Vaccination Vaccine Development 95

pharmaphorum

APRIL 27, 2022

Vir Biotechnology-partnered COVID-19 antibody Xevudy (sotrovimab) was the big contributor to the improved result, adding £1.3 Turnover of the antibody is likely to fall sharply however as the drug has lower efficacy against the prevailing Omicron BA.2 billion ($1.6 billion) to the company’s top-line of £9.8

Sales 97

Sales Antibody Vaccination Vaccine 97

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

Scienmag

SEPTEMBER 11, 2020

Credit: NIAID, 2020 A comprehensive analysis of antibody responses in coronavirus disease 2019 (COVID-19) patients could inform the development of an effective vaccine, according to a study published September 10 in the open-access journal PLOS Pathogens by Chao Wu and Rui Huang of Nanjing University Medical School, and colleagues.

Antibody 61

Antibody Vaccination Vaccine Development 61

Scienmag

DECEMBER 23, 2021

Credit: Julianna Han, Ward Lab at Scripps Research LA JOLLA, CA—Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles’ heel of influenza virus, making progress in the quest for a universal flu vaccine.

Vaccination 96

Vaccination Vaccine Research Antibody 96

Scienmag

FEBRUARY 10, 2022

The discovery, published Feb 8 in Science Translational Medicine, could inform the design of broad-acting vaccines and antibody therapies capable of stopping […].

Vaccination 76

Vaccination Vaccine Research Protein 76

Drug Discovery World

SEPTEMBER 8, 2023

Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 The European Commission’s Committee for Medicinal Products for Human Use (CHMP) recommended the drug for approval in the EU in August. subvariant.

Regulation 52

Regulation Vaccination Vaccine Medicine 52

Scienmag

DECEMBER 29, 2021

COVID-19 vaccination of expectant mothers elicits levels of antibodies to the SARS-CoV-2 outer “spike” protein at the time of delivery that don’t vary dramatically with the timing of vaccination during pregnancy and thus don’t justify delaying vaccination, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Vaccination 75

Vaccination Vaccine Protein Antibody 75

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8) million funding from UK Research and Innovation (UKRI).

Vaccination 105

Vaccination Vaccine Immune Response Scientist 105

Drug Discovery World

AUGUST 9, 2023

A new respiratory syncytial virus (RSV) vaccine candidate has achieved positive safety and immunogenicity results in a Phase I clinical study of RSV-naïve participants between the ages of six and 36 months. MV-012-968 is being developed by Meissa Vaccines as a needle-free, adjuvant-free vaccine to protect infants and toddlers from RSV.

Vaccination 52

Vaccination Vaccine Antibody Medicine 52

Drug Discovery World

MARCH 27, 2023

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. Despite the availability of statins and the approval of PCSK9-targeting medicines, there is still a need for new therapies.

Vaccination 52

Vaccination Vaccine Antibody Immune Response 52

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 104

Vaccination Vaccine Research Immune Response 104

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccination 98

Vaccination Vaccine Antibody Development 98

pharmaphorum

JANUARY 15, 2021

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month. Both of these vaccines require two doses, as does the most recently approved shot from Moderna, which is due to arrive in the UK in the spring.

Vaccination 116

Vaccination Vaccine Immune Response Antibody 116

Scienmag

DECEMBER 23, 2021

A team led by scientists at Weill Cornell Medicine, Scripps Research and the University of Chicago has identified an important site of vulnerability on influenza viruses—a site that future influenza vaccines and antibody therapies should be able to target to prevent or treat infections by a broad set of influenza strains.

Vaccination 67

Vaccination Vaccine Scientist Antibody 67

pharmaphorum

AUGUST 11, 2022

Figures from the UK Office for National Statistics (ONS) have revealed that the number of people with higher levels of COVID-19 antibodies in their blood is declining quickly – leading to calls for booster vaccination campaigns to be started as soon as possible. in March to 71.9% in mid-July. . “The new Omicron BA.4 by mid-July.

Antibody 52

Antibody Immune Response Vaccination Vaccine 52